Review of: "[Case Study] Targeting the Warburg Effect with the Glucose Mutation Theory: A Case Study of 36-Year-Old Female Treated for Stage IV Metastatic TPBCUsing Glucosodiene Over a 15-Day Period"

Angelika Długosz-Pokorska[1]

1 Medical University of Lodz

Potential competing interests: No potential competing interests to declare.

I recommend publication of this manuscript. The article tackled the title's question with clarity and coherence. The manuscript presents compelling evidence regarding the efficacy of Glucosodiene in the treatment of metastatic Triple-Negative Breast Cancer (TNBC) to the bones, as highlighted in a case report. The study demonstrates Glucosodiene's potential as a primary therapeutic agent, showcasing its remarkable ability to induce the complete disappearance of active foci within the bones within a short treatment period.

The authors provide detailed insights into the treatment protocol, including dosage recommendations and synthesis methodology, which is crucial for clinical application. The safety and efficacy of Glucosodiene are supported by rigorous experimentation, with positive patient outcomes observed after a mere 15-day treatment cycle.

The manuscript effectively emphasizes the importance of biomarker monitoring, particularly Alkaline Phosphatase (ALP), Carcino-Embryonic Antigen (CEA), and Antigen CA 15-3, in assessing treatment response and disease progression. Significant reductions in these biomarkers post-treatment signify a favorable response to Glucosodiene therapy, suggesting its potential to suppress tumor activity and reduce tumor burden.

In conclusion, the study presents promising results regarding Glucosodiene's efficacy in metastatic Triple-Negative Breast Cancer. The comprehensive evaluation, supported by PET scan examinations and biomarker monitoring, underscores its potential as a primary therapeutic agent for aggressive forms of breast cancer. Further research and clinical trials are warranted to validate its effectiveness and establish its role in standard treatment protocols. With ongoing investigation and refinement, Glucosodiene holds promise as a valuable addition to the treatment arsenal against metastatic breast cancer, offering hope for improved patient outcomes and enhanced quality of life.